Gain Therapeutics (GANX) Common Equity (2020 - 2026)
Gain Therapeutics (GANX) posted quarterly Common Equity of $14.0 million for Q1 2026, up 142.35% year-over-year from $5.8 million in Q1 2025, and down 24.55% quarter-over-quarter from $18.6 million in Q4 2025.
Gain Therapeutics (GANX) Common Equity (2020 - 2026) Analysis & Trends
Gain Therapeutics' Common Equity history runs 7 years deep, the most recent figure standing at $14.0 million for Q1 2026.
- In Q1 2026, Common Equity rose 142.35% year-over-year to $14.0 million; the TTM figure through Mar 2026 stood at $14.0 million (up 142.35% YoY), while the FY2025 annual figure was $18.6 million, up 152.94% from the prior year.
- Common Equity for Q1 2026 stood at $14.0 million, down from $18.6 million in the prior quarter.
- The five-year high for Common Equity was $31.8 million in Q1 2022, with the low at $3.7 million in Q2 2025.
- The 5-year median for Common Equity is $11.8 million (2024), against an average of $13.6 million.
- Peak annual rise in Common Equity reached 152.94% in 2025, while the deepest fall reached 68.64% in 2025.
- Gain Therapeutics' Common Equity stood at $18.9 million in 2022, then tumbled by 33.38% to $12.6 million in 2023, then tumbled by 41.65% to $7.3 million in 2024, then soared by 152.94% to $18.6 million in 2025, then dropped by 24.55% to $14.0 million in 2026.
- Business Quant data shows GANX's Common Equity at $14.0 million in Q1 2026, $18.6 million in Q4 2025, and $5.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | Gain Therapeutics | 85.12 Mn | 85.12 Mn | - | 11.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.29 Mn |
| Mar 31, 2026 | 14.01 Mn |
| Dec 31, 2025 | 18.56 Mn |
| Sep 30, 2025 | 5.91 Mn |
| Jun 30, 2025 | 3.70 Mn |
| Mar 31, 2025 | 5.78 Mn |
| Dec 31, 2024 | 7.34 Mn |
| Sep 30, 2024 | 8.91 Mn |
| Jun 30, 2024 | 11.78 Mn |
| Mar 31, 2024 | 8.64 Mn |
| Dec 31, 2023 | 12.58 Mn |
| Sep 30, 2023 | 7.33 Mn |
| Jun 30, 2023 | 11.09 Mn |
| Mar 31, 2023 | 15.14 Mn |
| Dec 31, 2022 | 18.88 Mn |
| Sep 30, 2022 | 22.66 Mn |
| Jun 30, 2022 | 27.02 Mn |
| Mar 31, 2022 | 31.83 Mn |
| Dec 31, 2021 | 34.82 Mn |
| Sep 30, 2021 | 37.55 Mn |